The $14 billion acquisition would add the best-selling prostate cancer drug Xtandi to Pfizer's growing oncology portfolio.
Tribune Publishing, Molson Coors, Las Vegas Sands, Raycom Media, Huttig Building, Medivation, Career Education, Science Applications, HCP, Lantheus
Wells Fargo, Humana, Warner Music, Dynamic Materials, Medivation, Synchronoss Technologies, Sizmek, Lakeland Financial
